1. Chuanying Geng, Guangzhong Yang, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian, Wenming Chen*.Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era. Hematology .2023.28(1) . 2161222 .SCI |
2. Chengcheng Fu, Xiaohong Wang, Xian Cao, Lingjie Xu , Wang Liu, Jingnan Pi, Bin Wang, Wenming Chen*.The Clinical Characteristics of Immunoglobulin Light Chain Amyloidosis in the Chinese Population: A Systematic Scoping Review . Hematology .2023.4. 12-25 .SCI |
3. Yuan Jian, Zhiyao Zhang, Huixing Zhou, Guangzhong Yang, Chuanying Geng, Huijuan Wang, Wen Gao, Wenming Chen*.CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14) .Frontiers in Oncology .2022. 12 . 1061438 .SCI |
4. Guangzhong Yang. Chuanying Geng. Yuan Jian. Huixing Zhou. Wenming Chen*.Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.ADVANCES IN THERAPY .2022.39(8) .3799-3834 .SCI |
5. Wen Gao #, Yurong Zheng #, Runhua Zhang #, Gaifen Liu, Yuan Jian, Huixing Zhou, Zhiyao Zhang, Shuohua Chen, Shouling Wu*, Wenming Chen*.Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China .Cancer Epidemiology .2022.78.102168 .SCI |
6. 耿传营,杨光忠,王慧娟,周慧星,张之尧,菅原,陈文明*.CD56与新诊断多发性骨髓瘤的预后关系分析 .中华内科杂志 .2022.61(2) .164-171. |
7. 申曼,李新,杨光忠,张佳佳,汤然,黄仲夏,陈文明*.存活10年以上非移植多发性骨髓瘤25例临床分析 .中华血液学杂志 .2022.43(2).161-163 . |
8. Ying Wang# , Aijun Liu#, Tingting Xu, Jiahui Yin, Wenming Chen*.Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor .Clinical Medicine Insights-Oncology.2022.16.1-10 .SCI |
9. 杨光忠,王国蓉,王慧娟,章艳茹,吴垠,李燕郴,刘爱军,冷芸,高文,陈文明*.新药时代多发性骨髓瘤患者自体造血干细胞移植后微小残留病状态的预后价值 .中华医学杂志 .2022.102(30).2345-2350 . |
10. Yuan Jian, Huixing Zhou, Yidan Wang, Zhiyao Zhang, Guangzhong Yang, Chuanying Geng, Ying Tian, Wen Gao*, Wenming Chen*.Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients .Cancer Medicine .2022.epub. .SCI |
11. Yun Leng#, Xiaoyan Hu#, Lin Li#, Jewel Nkwocha, Toshihisa Satta, Kanika Sharma, Maciej Kmeiciak, Huixing Zhou, Zhiyao Zhang, Liang Zhou, Wenming Chen*, Steven Grant*.Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells . HEMATOLOGICAL ONCOLOGY .2022.7(5) .1-10.SCI |
12. Chuanying Geng, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian, Guangzhong Yang*, Wenming Chen*.Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation. . BMC CANCER .2022. 22(1) . 1349 .SCI |
13. 陈文明*,林泽宇.复发难治多发性骨髓瘤的诊断与治疗困惑 .中华医学杂志 .2022.102(30) . 2311-2314 . |
14. 冷芸,王慧娟,周慧星,张之尧,陈文明*.多发性骨髓瘤伴发第二肿瘤与恶性肿瘤伴发多发性骨髓瘤的临床特征分析.中华医学杂志 .2022. 102(32) . 2523-2520 . |
15. 蔡真,陈文明*.复发难治性多发性骨髓瘤治疗解读 . 中华内科杂志 .2022. 61(5) . 469-473 . |
16. Man Shen, Guangzhong Yang, Xin Li, Chuanying Geng, Zhongxia Huang*, Wenming Chen*.At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.LEUKEMIA & LYMPHOMA.2021.62(12).2992-3001.SCI |
17. Jing Jia, Wenming Chen*.Role of radiation therapy in primary tonsil large B cell lymphoma: a SEER-based analysis.Radiation Oncology.2021.16(1).193.SCI |
18. 杨光忠,耿传营,吴垠,刘爱军,冷芸,李燕郴,高文,陈文明* .国产硼替佐米(昕泰®)治疗多发性骨髓瘤的临床疗效及安全性.中国癌症防治杂志.2021.13(4).385-388.核心期刊 |
19. Yu Kang, Zi-Liang Hou, Guang-Zhong Yang, Xiao-Juan Wang, Wen-Ming Chen*, Huan-Zhong Shi*.Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma.International Journal of General Medicine.2021.14.649-657.SCI |
20. 耿传营,杨光忠,王国蓉,王慧娟,周慧星,张之尧,菅原, 陈文明*.自体造血干细胞移植治疗初治多发性骨髓瘤的临床分析.中华血液学杂志.2021.42(5).390-395.核心期刊 |
21. 陈文明*.多发性骨髓瘤诊治进展.临床内科杂志.2021.38(12).793-796.核心期刊 |
22. Juan Du, Baijun Fang, Jian Li, Jie Jin, Shunqing Wang, Dehui Zou, Zhen Cai, Hongxiang Wang, Jianda Hu, Wei Li, Chengcheng Fu , Zonghong Shao, Zhongjun Xia, Peng Liu, Ting Niu, En-Tzu Tang , Amy S Kimball, Jian Hou*, Wenming Chen*.A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.INTERNATIONAL JOURNAL OF HEMATOLOGY.2021.113(3).422-429.SCI |
23. Minqiu Lu, Yin Wu, Wen Gao, Ying Tian, Guorong Wang, Aijun Liu, Wenming Chen*.Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing.Frontiers in Genetics.2021.12.625019.SCI |
24. Huijuan Wang, Chuanying Geng*, Huixing Zhou, Zhiyao Zhang, Wenming Chen*.Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis.Oncology Letters.2021.21(4).295-301.SCI |
25. 杨光忠,高文,王国蓉,李燕郴,吴垠,刘爱军,冷芸,陈文明* .重组人促血小板生成素在多发性骨髓瘤患者自体外周血干细胞移植中的临床应用.中国癌症防治杂志.2021.13(4).380-384.核心期刊 |
26. Guang-Zhong Yang, Guo-Rong Wang, Yan-Chen Li, Yin Wu, Wen Gao, Wen-Ming Chen*.Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study.CHINESE MEDICAL JOURNAL.2021.134(16).1991-1993.SCI |
27. Chuanying Geng, Guangzhong Yang, Huijuan Wang, Zhiyao Zhang, Huixing Zhou, Wenming Chen*.The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.Biomed Research International.2021. .6689457.SCI |
28. Wu XX, Guo JY#, et al. .The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells.BRITISH JOURNAL OF HAEMATOLOGY.2020.190(5).741-752.SCI |
29. Wen Gao*, Yuan Jian#, Juan Du, Xiaozhe, Huixing Zhou, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Ranchen Li, Yin Wu, Weijun Fu*, Juan Li*, Wenming Chen*.Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.Cancer Medicine.2020.9(21).7819-7829.SCI |
30. Zhang ZY, et al..Serum exosomal microRNAs as novel biomarkers for multiple myeloma.HEMATOLOGICAL ONCOLOGY .2019.37(4) .409-417 . |
31. Lu MQ, et al..Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. .BMC Medical Genomics .2019.12(1) . 135-150 .SCI |
32. Chen WM, et al.1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.ONCOLOGIST.2019.24(11) . e1132-e1140 .SCI |
33. Hu Y, et al.Progress in the identification of gene mutations involved in multiple myeloma .OncoTargets and Therapy .2019.12. 4075–4080 .SCI |
34. Zhang Z, Li Z, Chen W.Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myelomaMM1R cells.Experimental and Therapeutic Medicine.2018.16(5).4253-4259.SCI |
35. Gao W, Li J, Jian Y, Yang G, Wu Y, Li Y, Len Y, Liu A, Tian Y, Wang H, Zhou H, Zhang Z, Chen W.Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy,but not ASCT consolidation.INTERNATIONAL JOURNAL OF HEMATOLOGY.2018.epub.epub.SCI |
36. Jia J, Wang H, Wu M, Zhang F, Liu X, Chen W, Liu A.Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib:A Case Report and Review of the Literature.ACTAHAEMATOLOGICA.2018.140(1).46-50.SCI |
37. Tian Y, Zhang Y, Zhu WQ, Chen XL, Zhou HB, Chen WM.Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma.Biomed Research International.2018.2018.9434637.SCI |
38. Zhou H,Jian Y, Chen W.Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma..INT J HEMATOL.2017.105(3).318-325 .SCI |
39. YinWu,Giaisi M, Köhler R, Krammer PH, Chen WM, Li-Weber M..Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model. .Cancer Letters.2017.389 .70-77.SCI |
40. Gao W, Guo WJ, Hou DY, Yang GZ, Wu Y, Li YC, Leng Y, Tang Y, Xu L, Liu JM,Wang H, Wang X, Zhang J, Zhao WS, Zhang L..Autoantibodies against β(1)-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients..Leuk Lymphoma..2017.59(3).717-724 .SCI |
41. Leng Y, Hou J, Jin J, Zhang M, Ke X, Jiang B, Pan L, Yang L, Zhou F, Wang J,Wang Z, Liu L, Li W, Shen Z, Qiu L, Chang N, Li J, Liu J, Pang H, Meng H, Wei P, Jiang H, Liu Y, Zheng X, Yang S.Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/ refractory multiple myeloma: a phase 2 study..Cancer Chemother Pharmacol.2017.79(6).1141-1149 .SCI |
42. Leng Y, Qiu L, Hou J, Zhao Y, Zhang X, Yang S, Xi H, Huang Z, Pan L, Chen W.. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma..Chin J Cancer..2016.35(1) .86.SCI |
43. Wang G. Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival .ACTA HAEMATOL-BASEL .2016.136(3) .140-146.SCI |
44. Zhu W,Chen WM.Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies..Medicine (Baltimore).2016.95(46) .e5202 . |
45. 指南.Second primary malignancies in multiple myeloma: an overview and IMWG consensus..Ann Oncol.2016.28(2).228-245.SCI |
46. Geng C, Hou J, Zhao Y, Ke X, Wang Z, Qiu L, Xi H, Wang F, Wei N, Liu Y, Yang S, Wei P, Zheng X, Huang Z, Zhu B,Chen W.A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma..Am J Hematol.2016.89(11).1037-42..SCI |
47. 指南.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma..Lancet Oncol.2016.17(8).e328-e346.SCI |
48. Yan D1, Wei P, An G, Chen W.Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.J Cardiothorac Surg.2013.8.149.SCI |
49. Gao W, Geng C, Zhang L, Li Y, Chen W, Wang C.Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.Hematology.2013.18(6).341-7.SCI |
50. Geng CY1, Liu N, Yang GZ, Liu AJ, Leng Y, Wang HJ, Li LH, Wu Y, Li YC, Chen WM..Differential protein expression profile between CD20 positive and negative cells of the NCI-H929 cell line.Asian Pac J Cancer Prev .2012.13(11).5409-13 .SCI |
51. Dispenzieri A, Kyle R, Merlini G,... Chen W, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.Leukemia.2009.23(2).215-24.SCI |